11/18
03:37 pm
nktr
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence [Yahoo! Finance]
Low
Report
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence [Yahoo! Finance]
11/18
03:30 pm
nktr
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Neutral
Report
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
11/10
09:59 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets [Yahoo! Finance]
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets [Yahoo! Finance]
11/8
02:48 am
nktr
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook [Yahoo! Finance]
Medium
Report
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook [Yahoo! Finance]
11/7
04:22 pm
nktr
Nektar Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Nektar Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/7
04:15 pm
nktr
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Low
Report
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
11/7
10:15 am
nktr
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Low
Report
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/6
06:00 pm
nktr
Nektar Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Nektar Therapeutics to Participate in Upcoming Investor Conferences
11/4
01:56 pm
nktr
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential [Yahoo! Finance]
Low
Report
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential [Yahoo! Finance]
11/4
08:30 am
nktr
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
Low
Report
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
11/4
08:19 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $7.00 price target on the stock.
Low
Report
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $7.00 price target on the stock.
10/31
06:00 pm
nktr
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
Low
Report
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
10/29
09:00 am
nktr
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
Medium
Report
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
10/28
05:36 pm
nktr
Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Medium
Report
Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
10/17
02:13 pm
nktr
Nektar sees promising phase 1 results of NKTR-255 in B-cell lymphoblastic leukemia [Seeking Alpha]
Low
Report
Nektar sees promising phase 1 results of NKTR-255 in B-cell lymphoblastic leukemia [Seeking Alpha]
10/17
12:23 pm
nktr
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia [Yahoo! Finance]
Neutral
Report
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia [Yahoo! Finance]
10/17
12:07 pm
nktr
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Medium
Report
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
9/30
03:24 pm
nktr
Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset [Seeking Alpha]
Low
Report
Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset [Seeking Alpha]
9/30
10:58 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
9/25
03:30 am
nktr
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
Medium
Report
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
9/3
09:00 am
nktr
Nektar Management to Present at Upcoming Investor Conferences
Medium
Report
Nektar Management to Present at Upcoming Investor Conferences